Vittorio G.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
- Phase II Randomized Trial of Atezolizumab Versus Atezolizumab Plus Bevacizumab in PD-L1 High Advanced Non-Small-Cell Lung Cancer
- Phase II Randomized Study on EGFR-TKI Sequencing with Dacomitinib and Osimertinib in Advanced EGFR-Mutant NSCLC
- Evaluation of Cabozantinib Efficacy in Non-Small Cell Lung Cancer Patients with MET Deregulation: A Phase II Single-Arm Study
Data & Insights
Has run more than one trial at 22 of 56 partner sites.
Specializations
Lung Cancer Research
This investigator specializes in advanced therapeutic approaches for non-small cell lung cancer (NSCLC), with particular emphasis on targeted treatment strategies and innovative combination therapies.
- Targeted molecular therapies in NSCLC treatment
- PD-L1 expression patterns in lung cancer
- MET deregulation mechanisms
The investigator focuses on developing personalized treatment approaches based on specific molecular markers.
Immunotherapy Research
Expertise centers on immunotherapeutic interventions in oncology, particularly investigating immune checkpoint inhibitors and their combinations with other therapeutic agents.
- Novel immunotherapy combinations
- First-line treatment strategies
- Treatment optimization for advanced disease
The research explores innovative combinations of immunotherapy with antiangiogenic treatments.
Molecular Oncology
The investigator specializes in molecular targeted therapies with a focus on specific genetic alterations and their role in cancer treatment.
- MET amplification studies
- Biomarker-driven treatment approaches
- Resistance mechanism analysis
Research activities concentrate on understanding and targeting specific molecular pathways in cancer progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.